SCHEMBL15525325

SCHEMBL15525325

CCCC[Sn](CCCC)(CCCC)c1cnn(C2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.48
▸ CRBN Q96SW2 1/20 0.48
▸ JAK3 P52333 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ GPR119 Q8TDV5 5/20 0.41
▸ MET P08581 2/20 0.40
▸ FGFR1 P11362 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ FGFR4 P22455 1/20 0.40
▸ FGFR3 P22607 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ TNK2 Q07912 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30990437 0.78 GPR119 (0.42) JAK3JAK2GPR119PDE4APDE4B
SCHEMBL31640157 0.78 DDB1 (0.48) DDB1CRBNGPR119LMNAMEN1
SCHEMBL12121174 0.77 DDB1 (0.57) DDB1CRBNCCNCCDK8GPR119
SCHEMBL16096491 0.77 DDB1 (0.57) DDB1CRBNCCNCCDK8GPR119
SCHEMBL30991201 0.77 GPR119 (0.42) GPR119LMNAMEN1ALDH1A1GAA
SCHEMBL22550045 0.77 DDB1 (0.52) DDB1CRBNJAK3JAK2PTK2
SCHEMBL30890232 0.77 DDB1 (0.54) DDB1CRBNJAK3JAK2PTK2
SCHEMBL1427617 0.76 DDB1 (0.56) DDB1CRBNJAK3JAK2PTK2
SCHEMBL520714 0.76 DDB1 (0.56) DDB1CRBNJAK3JAK2PTK2
SCHEMBL29249379 0.76 DDB1 (0.56) DDB1CRBNCCNCCDK8GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838898-B1 SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF ADVINUS THERAPEUTICS LTD (IN) 2017-01-18 — — EP disclosed
US-9233983-B2 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2016-01-12 — — US disclosed
US-20150064196-A1 Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof IMPETIS BIOSCIENCES LIMITED (IN) 2015-03-05 — — US disclosed
EP-2838898-A1 SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2015-02-25 — — EP disclosed
WO-2013157022-A1 SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2013-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150064196-A1 Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof BTK, MALT1, LCK DDB1 3664/4885CRBN 3344/4885JAK3 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback